ACST Stock – (NASDAQ: ACST) is providing an update on the use

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use

ACST
-1.84%
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is actually giving an update on the use of its “at-the market” equity offering plan.

As earlier disclosed, Acasti entered into an amended as well as restated ATM sales agreement on June twenty nine, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to implement an “at-the market” equity offering system under which Acasti may issue as well as market from time to time the common shares of its having an aggregate offering price of up to seventy five dolars million in the Agents (the “ATM Program”).

ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the last distributions reported on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 common shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate gross proceeds to the Company of US$21.7 million. The ATM Shares ended up being marketed at prevailing market rates averaging US$1.0747 per share. No securities had been marketed through the facilities of the TSXV or maybe, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S 3 (No. 333 239538) as made effective on July seven, 2020, and also the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a consequence of the recent ATM sales, Acasti has a total of 200,119,659 typical shares issued and outstanding as of March 5, 2021.

The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with additional freedom in its continuous review process to check out as well as evaluate strategic options.

Approximately Acasti – ACST Stock

Acasti is actually a biopharmaceutical innovator that has historically centered on the research, development and commercialization of prescription medications using OM3 greasy acids delivered both as free fatty acids as well as bound-to-phospholipid esters, derived from krill oil. OM3 fatty acids have substantial clinical proof of safety and efficacy in lowering triglycerides in patients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for individuals with severe HTG.

Forward Looking Statements – ACST Stock

Statements in that press release which are not statements of current or historical fact constitute “forward-looking information” within the meaning of Canadian securities laws as well as “forward looking statements” to the meaning of U.S. federal securities laws (collectively, “forward-looking statements”). Such forward-looking statements include known and unknown risks, uncertainties, as well as other unknown factors that can cause the particular outcomes of Acasti to be materially different from historical outcomes or from any later outcomes expressed or implied by such forward looking statements. In addition to statements which explicitly describe these kinds of risks and uncertainties, readers are actually urged to consider statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or other similar expressions to be uncertain and forward-looking. Readers are actually cautioned not to place undue reliance on these forward looking statements, which speak just as of the day of this press release. Forward-looking claims in that press release include, but aren’t limited to, information or statements concerning Acasti’s strategy, succeeding operations as well as the review of its of strategic options.

The forward-looking assertions contained in this specific press release are expressly qualified in their entirety by this cautionary statement, the “Special Note Regarding Forward Looking Statements” section contained in Acasti’s latest annual report on Form 10-K and quarterly report on Form 10 Q, which are readily available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and on the investor section of Acasti’s site at www.acastipharma.com. Most forward-looking assertions in that press release exist as of the day of this press release.

ACST Stock – Acasti does not undertake to upgrade any such forward looking statements whether as a direct result of information which is new, future events or otherwise, except as required by law. The forward looking statements contained herein are also subject generally to risks and assumptions as well as uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities as well as The Canadian and exchange Commission securities commissions, like Acasti’s newest annual report on Form 10-K and quarterly report on Form 10 Q under the caption “Risk Factors“.

 

ACST Stock – (NASDAQ: ACST) is actually providing an update on the use